MADISON, Wis., Dec. 3, 2021 /PRNewswire/ — Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive Node, Endocrine Responsive Breast Cancer, or RxPONDER, trial were published in The New England Journal of Medicine. The study, led by the independent SWOG Cancer Research Network and sponsored by